search
Back to results

Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain (RCT)

Primary Purpose

Scoliosis

Status
Suspended
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Clonidine
Morphine
Sponsored by
Dr. Jean A. Ouellet, MD, FRCSC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scoliosis focused on measuring Post-operative pain

Eligibility Criteria

10 Years - 21 Years (Child, Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Females* aged between 10 and 21 years old
  • Scheduled to undergo anterior or posterior spinal fusion surgery for AIS with instrumentation
  • Ability to adequately understand and respond to outcome measures
  • No previous major orthopedic surgery
  • Any ethnic background

Exclusion Criteria:

  • Children with history of allergies to Clonidine or it's excipients in either injection or tablet formulation (see respective monograph)
  • Children with history of galactose intolerance
  • Children with history of myocardial disease, arrhythmias, cerebrovascular disease, Raynaud's/Thromboangiitis obliterans or chronic renal failure diagnosis based on history and physical
  • Children taking anti-hypertensive agents (diuretics, vasodilators, beta-blockers, ace-inhibitors)
  • History of depression
  • Inability of the child to speak English or French
  • Diagnosed with developmental delay that would interfere with understanding the questions being asked (autism, mental retardation)
  • Children with major chronic medical conditions (ASA status III or higher)
  • Pregnancy excluded by an in hospital testing the night before surgery

Sites / Locations

  • Shriners Hospitals for Children - Canada

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Opt-Clonidine

Sub-opt-Clonidine

Opt-Morphine

Sub-opt-Morphine

Arm Description

Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)

Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)

Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)

Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)

Outcomes

Primary Outcome Measures

QST
Evaluate if pre-operative QST can identify if patients will have high pain intensity peri-operatively and at 6 months post-operatively.

Secondary Outcome Measures

Clonidine
Peri-operative use of an alpha-2 adrenergic receptor agonist enhances the efficacy of the descending inhibitory system of patients with sub-optimal CPM efficacy before surgery by decreasing pain after surgery.

Full Information

First Posted
May 15, 2018
Last Updated
December 6, 2020
Sponsor
Dr. Jean A. Ouellet, MD, FRCSC
search

1. Study Identification

Unique Protocol Identification Number
NCT03537612
Brief Title
Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
Acronym
RCT
Official Title
Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Suspended
Why Stopped
Do to our inability to meet recruitment targets - Sponsor stopped funding. Looking for new sponsor and protocol modifications
Study Start Date
June 22, 2018 (Actual)
Primary Completion Date
June 1, 2021 (Anticipated)
Study Completion Date
December 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr. Jean A. Ouellet, MD, FRCSC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The overall goal of this proposal is to determine if quantitative sensory testing (QST) assessing pain modulation can be used as a clinical tool to optimize perioperative pain management. The central hypothesis is that the identification of patient's sensory pain profile allows personalizing therapeutic approaches to improve individualized pain management and thus prevents pain chronicity.
Detailed Description
The primary objective of this study is to evaluate if pre-operative QST can identify if patients will have high pain intensity peri-operatively and at 6 months post-operatively. Evaluation of the intensity and chronicity of pain and the function of the descending inhibitory system through a short QST procedure before surgery and six months after surgery will be carried out. In addition, evaluation of the patient's physical and emotional functioning, and exploration of the potential biological underlying mechanisms will also be assessed at the same time points. The secondary objective of this study is to determine if the peri-operative use of an alpha-2 adrenergic receptor agonist enhances the efficacy of the descending inhibitory system of patients with sub-optimal CPM efficacy before surgery by decreasing pain after surgery. Consequently, this pharmacological intervention may also reduce the incidence of acute and chronic pain after surgery. Evaluation of the pain intensity and the function of the descending inhibitory system through a short QST procedure six weeks after surgery and six months after surgery in patients receiving Clonidine or placebo during the perioperative period will be done. In addition, evaluation of the patient's physical and emotional functioning, and exploration the potential biological underlying mechanisms at the same time points will be assessed. Lastly, evaluation of potential biomechanical alterations in 3D related to pain in children reporting presence of back pain pre and post spine surgery will be looked at. The hypothesis is that patients undergoing spine surgery with poor inhibitory pain response will have less pain in the immediate and long-term period when treated prophylactically with Clonidine in the perioperative period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scoliosis
Keywords
Post-operative pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Double-blind, randomized
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Opt-Clonidine
Arm Type
Experimental
Arm Description
Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
Arm Title
Sub-opt-Clonidine
Arm Type
Experimental
Arm Description
Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
Arm Title
Opt-Morphine
Arm Type
Active Comparator
Arm Description
Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
Arm Title
Sub-opt-Morphine
Arm Type
Active Comparator
Arm Description
Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
Intervention Type
Drug
Intervention Name(s)
Clonidine
Intervention Description
Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
Intervention Type
Other
Intervention Name(s)
Morphine
Intervention Description
Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
Primary Outcome Measure Information:
Title
QST
Description
Evaluate if pre-operative QST can identify if patients will have high pain intensity peri-operatively and at 6 months post-operatively.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Clonidine
Description
Peri-operative use of an alpha-2 adrenergic receptor agonist enhances the efficacy of the descending inhibitory system of patients with sub-optimal CPM efficacy before surgery by decreasing pain after surgery.
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
3D Images 3D Biomechanical Alterations
Description
Evaluate the potential biomechanical alterations in 3D related to pain in children reporting presence of back pain pre and post spine surgery.
Time Frame
6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Females* aged between 10 and 21 years old Scheduled to undergo anterior or posterior spinal fusion surgery for AIS with instrumentation Ability to adequately understand and respond to outcome measures No previous major orthopedic surgery Any ethnic background Exclusion Criteria: Children with history of allergies to Clonidine or it's excipients in either injection or tablet formulation (see respective monograph) Children with history of galactose intolerance Children with history of myocardial disease, arrhythmias, cerebrovascular disease, Raynaud's/Thromboangiitis obliterans or chronic renal failure diagnosis based on history and physical Children taking anti-hypertensive agents (diuretics, vasodilators, beta-blockers, ace-inhibitors) History of depression Inability of the child to speak English or French Diagnosed with developmental delay that would interfere with understanding the questions being asked (autism, mental retardation) Children with major chronic medical conditions (ASA status III or higher) Pregnancy excluded by an in hospital testing the night before surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean A Ouellet, MD
Organizational Affiliation
Shriners Hospital for Children - Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shriners Hospitals for Children - Canada
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A 0A9
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain

We'll reach out to this number within 24 hrs